推动製药业永续性的成长机会和经营模式

Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry

出版日期: 2024年01月09日 | 出版商:

Frost & Sullivan | 英文 70 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

绿色产品、设计创新和利益相关者相关人员支持永续性努力

由于《欧洲绿色新政》和《巴黎协定》，製药（製药）产业的法规正在发生重大变化。这些变化迫使製药公司采取更环境永续的做法。随着全球药品需求的增加，製药公司的研发和製造基础设施不断扩大，导致环境足迹和温室气体 (GHG)排放增加。因此，为了因应这些发展，地方环境法规变得更加严格。此外，自 COVID-19 以来，製药公司更加意识到永续性的重要性，并正在采取措施来实现环境、社会和公司治理(ESG) 目标。公司正在适应不断变化的法规，以保持市场竞争力。值得注意的是，投资者越来越关注 ESG 评级，并更愿意根据公司的永续性努力、气候相关资讯揭露和企业社会责任实践来为公司提供资金。这就是我正在做的事情。

永续 & Sullivan 的这项研究重点关注製药业的永续性，使用 6P 框架（政策、产品、流程、人员、合作伙伴关係、平台）进行了详细讨论。这项研究包括全球和区域监管机构和分析师对政策及其对製药行业参与者和其他医疗保健相关人员的影响的主要观点。

本研究讨论了推动永续性计画发展的主要趋势和因素，以及采用的阻碍因素及其影响。本研究确定了支持产业相关人员加强永续性实践的最普及和新兴的经营模式经营模式，并确定了实施 6P 和实现永续发展目标的最佳实践。它展示了製药业公司在永续性领域的行动，并将其 ESG 计划与 6P 框架相对应。

战略问题

为什么成长如此困难？
The Strategic Imperative 8（TM）
製药业永续性的三大战略挑战的影响
成长机会推动Growth Pipeline Engine（TM）

成长机会分析

分析范围
製药业永续性和 CE 实践的 6P 框架
依医药价值链中的措施细分
生长促进因子
成长阻碍因素
实现整个製药价值链的永续性
温室气体排放范围概述
促进永续性的全球政策
促进永续性的区域政策/倡议
政策影响分析
推动医药价值链永续性的趋势
实现永续性的经营模式
四大经营模式- 影响概述
从公司到行动—永续发展目标和6P框架之间的合作

永续研究：产品

概述 -永续性产品
未来的重点领域—永续研究
特色产品 - 环保研究解决方案
永续原料 - 海洋药物的研发

永续製造：流程

製造业的永续性- 接触点
概述 - 实现永续性的过程
未来重点领域—永续製造
特色工艺-脱碳技术介绍
从政策到平台路径上智慧工具的未来前景

永续包装与分销：合作伙伴关係

合作伙伴关係是公司之间实现永续性的机会
未来的重点领域—永续包装与分销
合作重点 - CE 生命週期评估 (LCA)
未来展望－技术支援的设计创新

6P的实施

J&J
AZ
辉瑞公司
PPS
安靠

成长机会宇宙

成长机会 1：永续研究，贝南设计
成长机会 2：减少医药价值链中的碳足迹
成长机会3：基于ESG的成长策略平台
成长机会4：医药废弃物的永续管理
图表列表
免责声明

简介目录

Product Code: PFA4-52

Eco-friendly Products, Design Innovation, and Multi-stakeholder Partnerships Support Sustainability Initiatives

The pharmaceutical (pharma) industry is undergoing significant regulatory changes resulting from the European Green Deal and the Paris Agreement. These changes require pharma companies to adopt more environmentally sustainable practices. With the increasing demand for drugs globally, pharma R&D and manufacturing infrastructure has grown, leading to a larger environmental footprint and rising greenhouse gas (GHG) emissions. As a result, regional environmental regulations have become more stringent in response to these developments. Additionally, post-COVID-19, pharma companies have become more aware of the importance of sustainability and are adopting measures to achieve their environmental, social, and corporate governance (ESG) goals. Companies are aligning their operations with changing regulations to stay competitive in the market. Notably, investors are increasingly focused on ESG credit ratings, preferring to fund companies based on their sustainability efforts, climate-related disclosures, and corporate social responsibility practices.

This Frost & Sullivan study focuses on sustainability in the pharmaceutical industry and offers a detailed discussion on the implementation of the 6P framework, namely, policies, products, processes, people, partnerships, and platforms, by pharma value chain companies for their ESG strategy implementation and the fulfillment of United Nations Sustainable Development Goals (SDGs). The study includes key global and regional regulations and analyst perspectives on the policies and their implications for pharmaceutical industry participants and other healthcare stakeholders.

The study discusses key trends and factors driving the growth of the sustainability program as well as restraints to adoption and their implications. The study identifies the most prevalent and emerging business models that are supporting industry stakeholders in enhancing their sustainability practices and maps the best practices to 6P implementation and SDG Goal fulfillment. Pharma industry companies to action in the sustainability space are provided, and the ESG programs are mapped against the 6P framework.

Segmentation is based on the sustainability initiatives of pharma value chain companies across research (products), manufacturing (processes), and packaging and distribution (partnerships), covering detailed analysis of each segment's current focus, future implications, and prospects for stakeholders.

The ESG focus, unique sustainability initiatives, and 6P implementation case studies of Johnson & Johnson, Astra Zeneca, Pfizer, Piramal Pharma Solutions, and Amcor are discussed. The study concludes with a detailed discussion of growth opportunities in the sustainability space.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives for Sustainability in the Pharmaceuticals Industry
Growth Opportunities Fuel the Growth Pipeline Engine™